Evidence map›Paper›PMID 39696842›Full record

ArticleESC heart failure2025

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats.

Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge-Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Einar Sjaastad NordénUniversity of Oslo, Oslo University Hospital and Oslo New University College, Oslo, Norway.
Bård Andre BendiksenUniversity of Oslo, Oslo University Hospital and Oslo New University College, Oslo, Norway.
Kaja Knudsen BergoUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Emil Knut Stenersen EspeUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Gary McGinleyUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Almira HasicUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Ida Marie Hauge-IversenUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Hege Katrin UglandUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Xin ShenUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Michael FriskUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Nishani S MabotuwanaUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
William E LouchUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Rizwan I HussainAgiana Pharmaceuticals AS, Oslo, Norway.
Lili ZhangUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Ivar SjaastadUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Alessandro CataliottiUniversity of Oslo and Oslo University Hospital, Oslo, Norway.
Geir ChristensenUniversity of Oslo and Oslo University Hospital, Oslo, Norway.

Funding

Anders Jahres fond til vitenskapens fremmeKG Jebsen Center for Cardiac ResearchOlav Raagholt og Gerd Meidel Raagholts stiftelseOslo New University CollegeRakel og Otto Kristian Bruun's LegatSimon Fougner Hartmanns Family Fund
6 · The paper itself

Abstract

aimsSacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction following myocardial infarction (MI) remains uncertain. This study aimed at understanding the effects of Sac/Val on regional function after MI. METHODS AND

resultsMI or sham surgery was performed in Sprague-Dawley rats. Animals were randomized to treatment with Sac/Val, valsartan (Val) or vehicle (Veh). Magnetic resonance imaging was used to acquire left ventricular volumes and strain. Left ventricular tissue was obtained for wesern blotting, PCR and Masson's trichrome staining. Isolated cardiac fibroblasts were cultured with Veh, atrial natriuretic peptide (ANP), adrenomedullin (ADM) and sacubitrilat, and collagen expression assessed with droplet digital PCR.

resultsSac/Val reduced ventricular end-diastolic volume by 18% compared with Veh, and preserved circumferential systolic strain in the zone proximal to infarction compared with sham after 42 days of treatment (peak strain ± SEM: sham: -0.19 ± 0.01%; Sac/Val: -0.14 ± 0.02%; Val: -0.10 ± 0.02%; Veh: -0.10 ± 0.02%). Masson's trichrome staining demonstrated lower fibrotic deposition in the intermediate zone with Sac/Val treatment than Veh (sham: 2.29 ± 0.17%; Sac/Val: 2.31 ± 0.27%; Val: 3.22 ± 0.60%; Veh: 4.14 ± 0.48%). The amounts of the pro-apoptotic caspase 3 cleavage fragments p19/17 were 89% higher in Val than sham, with Sac/Val showing no significant increase compared with sham. Collagen expression in human fibroblast culture was lower in cells co-treated with sacubitrilat and ANP, an effect not observed with sacubitrilat/ADM co-treatment.

conclusionsSac/Val preserves in vivo myocardial function in the region most proximal to MI in rats and reduces left ventricular dilatation. These effects may be related to a reduction in both fibrosis and pro-apoptotic signalling.

Indexed as

AminobutyratesHeart VentriclesMyocardial InfarctionTetrazolesValsartanVentricular Function, LeftVentricular RemodelingAngiotensin Receptor AntagonistsAnimalsBiphenyl CompoundsDisease Models, AnimalDrug CombinationsMaleRatsRats, Sprague-DawleyAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanARNiHeart failureMyocardial infarctionRegional functionSacubitril/valsartan

Identifiers

PMID39696842
PMCPMC11911584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.